Non-invasive physical plasma as an innovative physical approach for the oncological therapy of skeletal sarcomas

https://doi.org/10.29328/journal.jro.1001042 Human osteosarcoma is the most common malignant bone tumor with an annual incidence of two cases per 1 million population. Osteosarcoma account for 60% of all malignant bone tumors occurring in childhood, followed by Ewing’s sarcoma [1-3]. In adults, however, chondrosarcoma is the most common primary bone malignancy. The prognosis of skeletal tumors depends on their localization, histological typing, and the degree of metastasis. The therapeutical set-up is oriented toward these modalities and for osteosarcoma and Ewing sarcomas consists of preoperative, neoadjuvant chemotherapy, surgical tumor resection, and postoperative, adjuvant chemotherapy. With current therapies, the recurrence-free overall 5 year survival rate is approximately 60% [4-6]. In contrast, surgical resection is the treatment of choice for chondrosarcoma due to its phenotypic characteristics and resistance to chemotherapy and radiotherapy [7]. It is therefore important to look for new options for the treatment of osseous sarcomas. Due to its anti-oncological effect, one such option may be treated with physical plasma [8-10].